{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:29:53Z","timestamp":1787236193627,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is triggered by nCOV-19 adenovirus-vectored vaccines against SARS-CoV2. Pathogenesis has been mainly related to platelet activation via PF4-reactive antibodies that activate platelets and may cross-react with heparin. Data concerning optimal anticoagulation are anecdotal, and so far, there are scattered reports of danaparoid use in VITT management. Danaparoid has good efficacy and safety in treatment of heparin-induced thrombocytopenia. We report here our experience of the administration and monitoring danaparoid in VITT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We diagnosed a series of six hospitalized cases of VITT, based on the international diagnostic guidance. All VITT-related data were from the local electronic medical and laboratory record system and were analyzed with IBM SPSS Statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Predominately women in their late 40\u2019s developed VITT on average 24\u2009days (range 9\u201359) after the first ChAdOx1 dose. Clinical presentation included single or multiple venous and\/or arterial thrombosis, moderate thrombocytopenia and high D-dimer levels. After detecting PF4 antibodies subcutaneous danaparoid was our first-line antithrombotic treatment with an average duration of three weeks. The median plasma anti-FXa activity was in the lower part of the therapeutic range and during the first week of danaparoid administration clinical symptoms, platelet counts, and fibrin turnover resolved or significantly improved. The average duration of hospital admission was 10\u2009days [2\u201318]. One patient died but the other five patients recovered completely.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The clinical outcomes of our small cohort align with the earlier published reports, and support danaparoid as a rational option for the initial anticoagulation of VITT patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12959-021-00362-y","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T06:13:54Z","timestamp":1643955234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT"],"prefix":"10.1186","volume":"20","author":[{"given":"Lasse","family":"Myllylahti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Pitk\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Magnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Lassila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"issue":"10269","key":"362_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99\u2013111. https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1 Epub 2020 Dec 8. Erratum in: Lancet. 2021 Jan 9;397(10269):98. PMID: 33306989; PMCID: PMC7723445.","journal-title":"Lancet"},{"issue":"23","key":"362_CR2","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Gray G, Vandebosch A, C\u00e1rdenas V, Shukarev G, Grinsztejn B, et al. ENSEMBLE Study Group. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384(23):2187\u2013201. https:\/\/doi.org\/10.1056\/NEJMoa2101544 Epub 2021 Apr 21. PMID: 33882225; PMCID: PMC8220996.","journal-title":"N Engl J Med"},{"issue":"27","key":"362_CR3","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2034577 Epub 2020 Dec 10. PMID: 33301246; PMCID: PMC7745181.","journal-title":"N Engl J Med"},{"issue":"5","key":"362_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2035389 Epub 2020 Dec 30. PMID: 33378609; PMCID: PMC7787219.","journal-title":"N Engl J Med"},{"issue":"22","key":"362_CR5","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","volume":"384","author":"NH Schultz","year":"2021","unstructured":"Schultz NH, S\u00f8rvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021;384(22):2124\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2104882 Epub 2021 Apr 9. PMID: 33835768; PMCID: PMC8112568.","journal-title":"N Engl J Med"},{"issue":"22","key":"362_CR6","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021;384(22):2092\u2013101. https:\/\/doi.org\/10.1056\/NEJMoa2104840 Epub 2021 Apr 9. PMID: 33835769; PMCID: PMC8095372.","journal-title":"N Engl J Med"},{"key":"362_CR7","doi-asserted-by":"publisher","unstructured":"Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021;384(23):2202\u201311. https:\/\/doi.org\/10.1056\/NEJMoa2105385.","DOI":"10.1056\/NEJMoa2105385"},{"key":"362_CR8","unstructured":"Guidance from the Expert Haematology Panel (EHP) on Covid-19 Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT), https:\/\/b-s-h.org.uk\/media\/20075\/guidance-version-22-20210903.pdf"},{"issue":"4","key":"362_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1001\/jama.2021.9889","volume":"326","author":"M S\u00e1nchez van Kammen","year":"2021","unstructured":"S\u00e1nchez van Kammen M, Heldner MR, Brodard J, Scutelnic A, Silvis S, Schroeder V, et al. Frequency of Thrombocytopenia and Platelet Factor 4\/Heparin Antibodies in Patients With Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic. JAMA. 2021;326(4):332\u20138. https:\/\/doi.org\/10.1001\/jama.2021.9889 PMID: 34213527; PMCID: PMC8317004.","journal-title":"JAMA"},{"key":"362_CR10","doi-asserted-by":"publisher","unstructured":"Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost 2017 Nov;15(11):2099\u20132114. https:\/\/doi.org\/10.1111\/jth.13813. Epub 2017 Sep 28. PMID: 28846826.","DOI":"10.1111\/jth.13813"},{"key":"362_CR11","unstructured":"Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19), Interim guidance 19 July 2021, World Health Organization."},{"key":"362_CR12","doi-asserted-by":"publisher","unstructured":"Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 2006 Jun;95(6):967\u2013981. https:\/\/doi.org\/10.1160\/TH05-07-0489. PMID: 16732376.","DOI":"10.1160\/TH05-07-0489"},{"key":"362_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1076029620977702","volume":"27","author":"HN Magnani","year":"2020","unstructured":"Magnani HN. Rationale for the role of heparin and related GAG antithrombotics in COVID-19 infection. Clin Appl Thromb Hemost. 2020;27:1\u201326. https:\/\/doi.org\/10.1177\/1076029620977702.","journal-title":"Clin Appl Thromb Hemost"},{"key":"362_CR14","unstructured":"HIT \u2013 Hepariinin indusoima trombosytopenia https:\/\/www.hematology.fi\/sites\/default\/files\/uploads\/hit_ohje_2021.pdf"},{"issue":"19","key":"362_CR15","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1161\/CIRCULATIONAHA.120.049015","volume":"142","author":"F Daviet","year":"2020","unstructured":"Daviet F, Guervilly C, Baldesi O, Bernard-Guervilly F, Pilarczyk E, Genin A, et al. Heparin-Induced Thrombocytopenia in Severe COVID-19. Circulation. 2020;142(19):1875\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.049015 Epub 2020 Sep 29. PMID: 32990022; PMCID: PMC7643786.","journal-title":"Circulation"},{"issue":"6","key":"362_CR16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s12185-020-02943-5","volume":"112","author":"E Deruelle","year":"2020","unstructured":"Deruelle E, Ben Hadj Salem O, Sep Hieng S, Pichereau C, Outin H, Jamme M. Immune thrombocytopenia in a patient with COVID-19. Int J Hematol. 2020;112(6):883\u20138. https:\/\/doi.org\/10.1007\/s12185-020-02943-5 Epub 2020 Jul 16. PMID: 32677007; PMCID: PMC7365304.","journal-title":"Int J Hematol"},{"issue":"7","key":"362_CR17","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1111\/jth.15346","volume":"19","author":"J Thaler","year":"2021","unstructured":"Thaler J, Ay C, Gleixner KV, Hauswirth AW, Cacioppo F, Grafeneder J, et al. Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). J Thromb Haemost. 2021;19(7):1819\u201322. https:\/\/doi.org\/10.1111\/jth.15346 Epub 2021 Jun 11. PMID: 33877735; PMCID: PMC8362082.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"362_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/bjh.17619","volume":"195","author":"S Ramdeny","year":"2021","unstructured":"Ramdeny S, Lang A, Al-Izzi S, Hung A, Anwar I, Kumar P. Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT). Br J Haematol. 2021;195(3):299. https:\/\/doi.org\/10.1111\/bjh.17619 Epub 2021 Jul 9. PMID: 34097311; PMCID: PMC8239676.","journal-title":"Br J Haematol"},{"key":"362_CR19","doi-asserted-by":"publisher","unstructured":"Walter U, Fuchs M, Grossmann A, Walter M, Thiele T, Storch A, et al. Adenovirus-Vectored COVID-19 Vaccine-Induced Immune Thrombosis of Carotid Artery: A Case Report. Neurology. 2021. https:\/\/doi.org\/10.1212\/WNL.0000000000012576 Epub ahead of print. PMID: 34312301.","DOI":"10.1212\/WNL.0000000000012576"},{"issue":"8","key":"362_CR20","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3390\/jcm10081599","volume":"10","author":"ME Wolf","year":"2021","unstructured":"Wolf ME, Luz B, Niehaus L, Bhogal P, B\u00e4zner H, Henkes H. Thrombocytopenia and intracranial venous sinus thrombosis after \"COVID-19 vaccine AstraZeneca\" exposure. J Clin Med. 2021;10(8):1599. https:\/\/doi.org\/10.3390\/jcm10081599 PMID: 33918932; PMCID: PMC8069989.","journal-title":"J Clin Med"},{"key":"362_CR21","unstructured":"HUS \u2013 Astra Zenecan (AZ) rokotuksen j\u00e4lkeiset tromboosit, diagnostiikka ja hoito. (Our hospital`s guidance)"},{"key":"362_CR22","unstructured":"Safety of COVID-19 vaccines - Infectious diseases and vaccinations - THL. https:\/\/thl.fi\/en\/web\/infectious-diseases-and-vaccinations\/what-s-new\/coronavirus-covid-19-latest-updates\/transmission-and-protection-coronavirus\/vaccines-and-coronavirus\/safety-of-covid-19-vaccines (accessed May 5, 2021)."},{"issue":"18","key":"362_CR23","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","volume":"385","author":"S Pavord","year":"2021","unstructured":"Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021;385(18):1680\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2109908 Epub 2021 Aug 11. PMID: 34379914.","journal-title":"N Engl J Med"},{"issue":"10306","key":"362_CR24","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(21)01608-1","volume":"398","author":"RJ Perry","year":"2021","unstructured":"Perry RJ, Tamborska A, Singh B, Craven B, Marigold R, Arthur-Farraj P, et al. CVT After Immunisation Against COVID-19 (CAIAC) collaborators. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. Lancet. 2021;398(10306):1147\u201356. https:\/\/doi.org\/10.1016\/S0140-6736(21)01608-1 Epub 2021 Aug 6. PMID: 34370972; PMCID: PMC8346241.","journal-title":"Lancet"},{"issue":"11","key":"362_CR25","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1001\/jamaneurol.2021.3619","volume":"78","author":"M S\u00e1nchez van Kammen","year":"2021","unstructured":"S\u00e1nchez van Kammen M, Aguiar de Sousa D, Poli S, Cordonnier C, Heldner MR, van de Munckhof A, et al. Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. JAMA Neurol. 2021;78(11):1314\u201323. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3619 PMID: 34581763; PMCID: PMC8479648.","journal-title":"JAMA Neurol"},{"issue":"11","key":"362_CR26","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1111\/ene.15029","volume":"28","author":"K Krzywicka","year":"2021","unstructured":"Krzywicka K, Heldner MR, S\u00e1nchez van Kammen M, van Haaps T, Hiltunen S, Silvis SM, et al. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency. Eur J Neurol. 2021;28(11):3656\u201362. https:\/\/doi.org\/10.1111\/ene.15029 Epub 2021 Aug 4. PMID: 34293217; PMCID: PMC8444640.","journal-title":"Eur J Neurol"},{"issue":"3","key":"362_CR27","doi-asserted-by":"publisher","first-page":"CXVI","DOI":"10.1177\/23969873211030842","volume":"6","author":"JM Ferro","year":"2021","unstructured":"Ferro JM, de Sousa DA, Coutinho JM, Martinelli I. European stroke organization interim expert opinion on cerebral venous thrombosis occurring after SARS-CoV-2 vaccination. Eur Stroke J. 2021;6(3):CXVI\u2013XI. https:\/\/doi.org\/10.1177\/23969873211030842 Epub 2021 Jul 20. PMID: 34746428; PMCID: PMC8564159.","journal-title":"Eur Stroke J"},{"issue":"1","key":"362_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/ene.15113","volume":"29","author":"A van de Munckhof","year":"2022","unstructured":"van de Munckhof A, Krzywicka K, Aguiar de Sousa D, S\u00e1nchez van Kammen M, Heldner MR, Jood K, et al. Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS-CoV-2 vaccination. Eur J Neurol. 2022;29(1):339\u201344. https:\/\/doi.org\/10.1111\/ene.15113 Epub 2021 Oct 1. PMID: 34536256; PMCID: PMC8652752.","journal-title":"Eur J Neurol"},{"key":"362_CR29","doi-asserted-by":"publisher","unstructured":"Ferro JM, Canh\u00e3o P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the international study on cerebral vein and Dural sinus thrombosis (ISCVT). Stroke. 2004 Mar;35(3):664\u2013670. https:\/\/doi.org\/10.1161\/01.STR.0000117571.76197.26. Epub 2004 Feb 19. PMID: 14976332.","DOI":"10.1161\/01.STR.0000117571.76197.26"},{"key":"362_CR30","doi-asserted-by":"publisher","unstructured":"Ferro JM, Bousser MG, Canh\u00e3o P, Coutinho JM, Crassard I, Dentali F et al. European stroke organization. European stroke organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European academy of neurology. Eur J Neurol 2017 Oct;24(10):1203\u20131213. https:\/\/doi.org\/10.1111\/ene.13381. Epub 2017 Aug 20. PMID: 28833980.","DOI":"10.1111\/ene.13381"},{"issue":"12","key":"362_CR31","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1001\/jamaneurol.2019.2764","volume":"76","author":"JM Ferro","year":"2019","unstructured":"Ferro JM, Coutinho JM, Dentali F, Kobayashi A, Alasheev A, Canh\u00e3o P, et al. RE-SPECT CVT Study Group. Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial. JAMA Neurol. 2019;76(12):1457\u201365. https:\/\/doi.org\/10.1001\/jamaneurol.2019.2764 PMID: 31479105; PMCID: PMC6724157.","journal-title":"JAMA Neurol"},{"key":"362_CR32","doi-asserted-by":"publisher","unstructured":"Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e495S-e530S. https:\/\/doi.org\/10.1378\/chest.11-2303. Erratum in: Chest. 2015 Dec;148(6):1529. PMID: 22315270; PMCID: PMC3278058.","DOI":"10.1378\/chest.11-2303"},{"key":"362_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.thromres.2021.10.027","volume":"208","author":"HH Pitk\u00e4nen","year":"2021","unstructured":"Pitk\u00e4nen HH, Jouppila A, Helin T, Dulipati V, Kotimaa J, Meri S, et al. COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets. Thromb Res. 2021;208:129\u201337. https:\/\/doi.org\/10.1016\/j.thromres.2021.10.027 Epub ahead of print. PMID: 34768097; PMCID: PMC8571998.","journal-title":"Thromb Res"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-021-00362-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-021-00362-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-021-00362-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T06:19:52Z","timestamp":1643955592000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-021-00362-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["362"],"URL":"https:\/\/doi.org\/10.1186\/s12959-021-00362-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1006994\/v1","asserted-by":"object"}]},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]},"assertion":[{"value":"28 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yes","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Yes","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Harry Magnani was involved with the clinical development of danaparoid from 1980 to 2000 and in retirement has provided consultant services to various MAHs including the current license holder Aspen Pharma. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}